Compare Stocks → Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DMTKNASDAQ:GEMPNASDAQ:JYNTNASDAQ:KINNASDAQ:KLDO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMTKDermTech$0.64+8.3%$0.87$0.59▼$4.36$22.16M2.52319,633 shs435,580 shsGEMPGemphire Therapeutics$3.44-0.6%$4.97$0.24▼$1.49$51.16M2.82127,174 shs22,788 shsJYNTJoint$12.14+1.8%$11.52$7.31▼$16.48$179.43M1.5991,899 shs35,764 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsKLDOKaleido Biosciences$0.00$0.00▼$0.03$4K-0.064,361 shs935 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMTKDermTech-0.17%-10.99%-13.99%-53.10%-86.63%GEMPGemphire Therapeutics+1.18%-3.91%-20.74%+0.29%+391.43%JYNTJoint-0.83%-5.92%-8.94%+31.86%-25.82%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%This company has increased its dividend every year for 54 years (Ad)There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMTKDermTech0.8136 of 5 stars3.01.00.00.01.60.01.3GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AJYNTJoint2.5699 of 5 stars3.23.00.00.01.81.71.9KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMTKDermTech2.50Moderate Buy$2.38271.35% UpsideGEMPGemphire TherapeuticsN/AN/AN/AN/AJYNTJoint2.33Hold$21.5077.10% UpsideKINKindred BiosciencesN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest KLDO, GEMP, KIN, JYNT, and DMTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/19/2024DMTKDermTechLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$0.634/19/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$1.504/19/2024DMTKDermTechBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/5/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMTKDermTech$15.30M1.45N/AN/A$1.67 per share0.38GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AJYNTJoint$117.70M1.52$0.73 per share16.56$1.68 per share7.23KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMTKDermTech-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/2/2024 (Estimated)GEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AJYNTJoint-$9.75M-$0.66N/A24.28N/A-8.19%7.80%2.65%5/2/2024 (Confirmed)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ALatest KLDO, GEMP, KIN, JYNT, and DMTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AJYNTJoint-$0.03N/A+$0.03N/AN/AN/A 3/7/2024Q4 2023JYNTJoint$0.03$0.07+$0.04$0.89$29.63 million$30.61 million2/29/2024Q4 2023DMTKDermTech-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMTKDermTechN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AJYNTJointN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMTKDermTechN/A4.594.52GEMPGemphire TherapeuticsN/A0.670.67JYNTJoint0.081.321.32KINKindred Biosciences0.197.027.02KLDOKaleido BiosciencesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMTKDermTech20.45%GEMPGemphire Therapeutics17.53%JYNTJoint76.88%KINKindred Biosciences66.89%KLDOKaleido Biosciences81.56%Insider OwnershipCompanyInsider OwnershipDMTKDermTech5.10%GEMPGemphire Therapeutics22.70%JYNTJoint4.00%KINKindred Biosciences13.69%KLDOKaleido Biosciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDMTKDermTech20634.62 million32.86 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableJYNTJoint44414.78 million14.19 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionableKLDO, GEMP, KIN, JYNT, and DMTK HeadlinesSourceHeadlineKaleido Biosciences gets grant for glycan therapeutic preparation for reducing gastrointestinal inflammation in immune imbalancepharmaceutical-technology.com - April 17 at 8:49 AMKaleido Biosciences (OTC: KLDO)fool.com - April 5 at 9:01 PMKaleido and Emma Join Forces to Help Families Secure Their Financial Future: An Innovative Partnershipfinance.yahoo.com - April 4 at 9:34 AMChange in management Kaleido IDEO+ individual RESP portfoliosfinance.yahoo.com - April 2 at 6:40 PMHitachi is buying 13.3 Kaleido 3 e-notes for their workforcegoodereader.com - March 27 at 11:07 AMPocketbook Era Color is a new Kaleido 3 e-readergoodereader.com - March 19 at 9:41 PMKromodyne set to disrupt print embellishment with its Kaleido brand embellishmentsprintweek.in - February 10 at 7:43 AMMobiScribe Wave Color with Kaleido 3 display launchedgoodereader.com - February 8 at 7:08 PMNew Bigme S2 e-note with 7.8-inch Kaleido 3 display launchedgoodereader.com - January 23 at 10:23 AMTelefónica Tech leads in IoT management, according to Kaleido Intelligencetelefonica.com - January 12 at 9:18 AMiReader Color7 color e-reader with 7-inch Kaleido 3 display launchedgoodereader.com - December 23 at 7:14 AMMobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido Intelligencefinance.yahoo.com - December 20 at 9:27 AMKALEIDO INTELLIGENCE LIMITED: Mobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido Intelligencefinanznachrichten.de - December 20 at 9:27 AMKaleido Intelligence to Launch Huge Enterprise Connectivity Survey in 2024finance.yahoo.com - December 14 at 7:32 AMHyread Gaze Mini C with Kaleido 3 due out in March 2024goodereader.com - December 9 at 9:17 AMViCentra: Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetesfinanznachrichten.de - November 22 at 4:06 PMKaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetesmedindia.net - November 21 at 9:40 AMKaleido Intelligence recognises Eseye and Vodafone as IoT connectivity leadersiottechnews.com - November 14 at 4:45 PMEseye, G+D, Thales and Vodafone Recognised as Champion Connectivity Vendors by Kaleido Intelligencefinance.yahoo.com - November 14 at 8:19 AMFirst Look at the Reinkstone R1600C with Kaleido Plusgoodereader.com - November 13 at 10:22 AMLocal tech startup brings augmented reality to art marketbizjournals.com - November 7 at 5:59 PMKaleido Biosciences Inc KLDOmorningstar.com - November 5 at 2:57 PMNokia and NTT DATA Recognised as Champion Private Network Vendors by Kaleido Intelligencefinance.yahoo.com - October 24 at 8:08 AMPocketBook InkPad Color 3 with Kaleido 3 is coming out soongoodereader.com - October 19 at 7:22 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideViking Therapeutics Surges Sentiment for Triple Threat GLP-1PillApril 3, 2024 6:20 AMView Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill3 Cheap Stocks That Shouldn’t Be Cheap for Long March 26, 2024 9:49 AMView 3 Cheap Stocks That Shouldn’t Be Cheap for Long 3 Key Stocks Helping to Drive the EV RaceApril 12, 2024 9:25 AMView 3 Key Stocks Helping to Drive the EV RaceHow to Protect your Portfolio Against a Rising VIXApril 10, 2024 9:22 AMView How to Protect your Portfolio Against a Rising VIXAll Headlines Company DescriptionsDermTechNASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.JointNASDAQ:JYNTThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Kindred BiosciencesNASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.